Sensei Biotherapeutics reports 50% 6-month PFS for solnerstotug in PD-(L)1 resistant tumors at ESMO 2025

Sensei Biotherapeutics, Inc.

6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.
Complete response in Merkel cell carcinoma patient; duration of response 54+ weeks. Four of six responders had late onset responses (18-54 weeks).
Favorable safety: only six mild Grade 1 CRS events across all 98 patients; no new safety signals.
Phase 2 studies planned in 2L NSCLC and Merkel cell carcinoma in 2026, subject to FDA feedback and capital raise.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-242007
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2025-10-17T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.673867+00:00
generated_at: 2026-05-17T03:25:29.504980+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-242007
json_url: https://secwatch.observer/filing/0001193125-25-242007.json
markdown_url: https://secwatch.observer/filing/0001193125-25-242007.md
text_url: https://secwatch.observer/filing/0001193125-25-242007.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/0001193125-25-242007-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/d223319d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-242007

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.